Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Ideally, the postoperative inflammatory response is part of a well-orchestrated mechanism that contributes to tissue healing and rapid recovery. An exaggerated uncontrolled inflammatory response, however may lead to catabolism, tissue damage and organ failure. Omega-3 fatty acids may provide a means to alter cellular immune responses to the benefit of the patient. When omega-3 fatty acids are incorporated into membranes of inflammatory cells, they trigger intracellular signalling pathways that result in a less pro-inflammatory response. They modify gene and protein expression, modulate membrane protein activity and act as a reservoir for bioactive molecules. They also have a strong anti-inflammatory effect by mediating resolution of the inflammation. Furthermore, omega-3 fatty acids improve erythrocyte function, which is vital for an adequate microcirculation, tissue oxygenation and wound healing.

The investigators hypothesize that the perioperative administration of intravenous omega-3 fatty acids results in a rapid incorporation in immune cells and erythrocytes, thereby reducing the postoperative inflammatory response and improving erythrocyte function in patients undergoing colorectal surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical Center Alkmaar
• Treatments: Antioxidants; Tocopherols

Criteria

Inclusion Criteria:

• Patients (male or female) undergoing elective laparoscopic surgery for colon cancer

• Age between 60 and 80 years

• BMI between 20 kg/m2 and below 30 kg/m2

• Written informed consent

Exclusion Criteria:

• Participation in or having participated in another clinical trial within the previous 3 months

• Indications for continuously use of anticoagulant medication and no possibility to stop these medication perioperatively, for example patients with an artificial heart valve

• Pre-operative Hemoglobin<5.0 mmol/L

• Metastatic disease

• Very poor peripheral venous access

• Current history of inflammatory or infectious disease

• The use of anti-inflammatory drugs

• The use of thyroid medication

• The use of fish oil products or fish consumption more than 2 times a week

• Contra-indication for the use of Omegaven-Fresenius, including:

• General contra-indications for parenteral nutrition

• Allergy to fish or egg protein.